Lege Artis Medicinae

[ROSIGLITAZONE IN THE HEAT OF THE DEBATE]

POGÁTSA Gábor

DECEMBER 19, 2008

Lege Artis Medicinae - 2008;18(12)

[The meta-analysis by Nissen and Wolski suggested a potential ischemic cardiac side effect of rosiglitazone. Studies in order to verify this suggestion finished until now had a short duration and a low frequency of harmful cardiac events that made them unable to decide this question. Nevertheless, several running studies will presumably have an adequate follow-up period of ten or more years and the desired frequency of observed cardiac events. Completion of these studies and publication of their results can be expected in the following two years. Until then, the European Medicines Agency’s standpoint of 18th October 2007 will be valid stating the benefits of rosiglitazone surpass its risks.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Getting in Harmony]

KOLIN Péter

Lege Artis Medicinae

[The History of a Famous Left Ear]

GERLINGER Imre

Lege Artis Medicinae

[Similar to Similar – Homeopathy in Hungary]

KÖLNEI Lívia

Lege Artis Medicinae

[Created to Bonding – Daniel Goleman: Social Intelligence. Beyond IQ, Beyond Emotional Intelligence]

FERENCZI Andrea

Lege Artis Medicinae

[Coecum or Not?]

BALOGH István

All articles in the issue

Related contents

Lege Artis Medicinae

[POST-INFARCTION CARDIAC FAILURE]

TOMCSÁNYI János

[Recent advances in the care of acute myocardial infarction have resulted in more patients surviving myocardial infarction than earlier. However, heart failure is a common complication in these patients, which in turn is associated with substantial mortality, primarily due to a remodelling of the left ventricle that already starts in an early stage of the myocardial infarction. The aim of this review article is to present the pathomechanism of this remodelling and to discuss related therapeutic options. Current guidelines recommend the use of an angiotensin- converting enzyme inhibitor combined with or followed by an angiotensin receptor blocker, a beta-blocker, and an aldosterone antagonist in post-infarction patients with concomitant heart failure.]

Lege Artis Medicinae

[Lixisenatide: a new GLP-1-receptor agonist with mainly prandial effect for the treatment of patients with type 2 diabetes]

JERMENDY György

[Recently, lixisenatide, a new incretin mimetic GLP-1-receptor agonist with a mainly prandial effect has been registered for the treatment of patients with type 2 diabetes mellitus. The amino acid sequence of lixisenatide and that of human native GLP-1 is 50% identical. Due to its altered amino acid sequence and conformation, lixisenatide is resistant to inactivation by DPP-4. Lixisenatide is a specific agonist of GLP-1- receptors and its binding has a pharmacologic GLP-1-agonist effect. Lixisenatide is used subcutaneously, its normal daily dose is 1×20 μg. It is mostly used in combination with metformin, but it can be also used to supplement sulfanylurea or basal insulin therapy. Clinical efficiency of lixisenatide has been investigated in the phase-III GetGoal trials. In these trials, adequate glycaemic control and a marked decrease in postprandial blood glucose values were observed. During lixisenatide therapy, a decrease in body weight and no substantial increase in the risk of hypoglycaemia were observed, whereas transient gastrointestinal side effects might occur after initiation of treatment. Lixisenatide as an add-on treatment to basal insulin should be considered as a new treatment approach in the management of type 2 diabetes.]

LAM KID

[Calcium supplementation and the risk of cardiovascular disease - Real apprehension or picking the spin?]

SPEER Gábor

[Some data shows that calcium supplementation, a basic intervention for treating osteoporosis in postmenopausal women, may increase the risk of atherosclerotic vascular disease. Coronary artery calcified plaque is a marker for atheromatous plaque burden and predicts future risk of cardiovascular events. However, the deposition of calcium into the vascular wall is due to an active mechanism, involving such genes and proteins which play role in bone metabolism. In this work the data about the cardiovascular side effect of calcium supplementation are reviewed. Also, I demonstrate studies with the conclusions that calcium supplements with or without vitamin D do not increase the risk of cardiovascular events, especially that of myocardial infarction.]

Hypertension and nephrology

[Enjoyable and invisible risk: salt The role of the Hungarian Hypertension Society in the National Salt Intake Lowering Program: STOP-SÓ]

KISS István

[Cardiovascular disease accounts for more than 50% of Hungarian mortality and hypertension accounts for almost 50% of coronary heart disease and for more than 60% of stroke. High salt intake increases blood pressure and major and sustained consumption may cause high blood pressure. In Hungary more than 2.5 million people have hypertension and among them only 44% have their blood pressure under 140/90 mm Hg. Achieving target blood pressure is difficult as salt intake of the Hungarian population is higher than that recommended in every age group. Blood pressure control consists of proper combination of medical treatment and of nonmedical procedures. Among non-medical procedures weight loss, increase of physical activity, Mediterranean diet and decrease of salt intake are of value in blood pressure lowering. A daily salt intake of less than 6 grams is recommended in the Hungarian guideline and in the European one the recommendation is more rigorous. However in Hungary average salt intake is 18 grams among men and 14 grams among women. Responsibility of the individual person is inevitable in preserving health and preventing disease. A perfect example for this is the change of salt intake habits as it is demonstrated that decreasing salt intake results in the decrease of blood pressure. A daily decrease of 5 grams in salt intake results in 23% less stroke and 17% less cardiovascular disease. The Hungarian Society of Hypertension has joined among the first to the Hungarian Salt Intake Decreasing Programme and thus its activity is aimed at strengthening the public health subset of the Hungarian Cardiovascular Programme.]

Lege Artis Medicinae

[SUBSTANCE ABUSE AND CARDIOVASCULAR SYSTEM]

VÁLYI Péter

[Substance abuse is an immense problem in Hungary and around the world. Psychological effects of this condition are widely known for abusers and health care workers. Cardiovascular effects of illicit substances are much less well known and can develop as very severe diseases (myocardial infarction, extremely high blood pressure, intracerebral haemorrhage, sudden death etc.) and occur particularly in young people. The treatment of cardiovascular complications of substance abuse may differ from that accepted in non-abusers and some drugs (for example: β-blockers) may be contraindicated. In this review, the effects of substance abuse on the cardiovascular system are discussed, including effects of most commonly abused substances: cocaine, amphetamines, heroin, LSD, marijuana, inhalative substances. In this review the cardiovascular effects of sedato-hypnotics and most widely used substances (alcohol, nicotine, caffeine) are not adressed, since they are well known.]